Perspective Therapeutics, Inc.

CATX

CIK 0000728387 · Quarterly mode · latest period FY2023 (Q3) (ending 2023-09-30) · sourced from SEC EDGAR

At a glance · FY2023 (Q3)

Revenue
$2M
↑+27.3% +$468Kvs FY2022 (Q3)
Gross Profit
$738K
↑+78.3% +$324Kvs FY2022 (Q3)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
50/100
  • Profitability
    0ROIC -35.8% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 5.17 (above 1.5 = solid)
  • Leverage
    100D/E 0.01 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.02x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +27.3% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$13M
investment in PP&E
Stock-based comp (TTM)
$9M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$267M
everything owned
Total liabilities
$60M
everything owed
Stockholders' equity
$207M
shareholder claim
Net debt
$-29M
Net cash position ($29M)

Recent performance · 61 quarters

Revenue↑+27.3% +$468K
$2M
Net Income↓-71.7% -$11M
$-26M
Free Cash Flow↑+65.3% +$10M
$-5M
Operating Margin↓-201.1pts
-446.2%

Drill down